Brochure: Biologics workflow solutions brochure
Biologics solutions from discovery to manufacturing.
List view / Grid view
Biologics solutions from discovery to manufacturing.
Solutions to help you understand viral diseases and translate your research findings into better treatments and vaccines.
Complete solutions for neurological disease research and discovery - helping you to better understand diseases to improve patient outcomes.
A wide range of tools to support your immuno-oncology research and help redefine and develop tailored, life-changing immunotherapies to fight cancer.
Solutions to aid understanding of cellular and molecular pathways in diabetes and translate these findings into prevention and treatment strategies.
Remdesivir is being prescribed under FDA emergency use authorisation as a treatment for patients with COVID-19.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
Neurological symptoms have been observed in COVID-19 patients. The link between SARS-CoV-2 and the CNS is critical to developing effective treatments
COVID-19 has affected nearly every Pharma industry. The development of a vaccine is challenging the world’s finest researchers and clinicians.
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
Harmonising drug-target binding data analytics looks at building a single, integrated software platform for a future pharma research and development digital ecosystem. This webinar, sponsored by PerkinElmer, outlined the fundamentals of a design process where an experimental analytics data workflow was integrated into a more seamlessly interactive digital platform.
Data integrity and computerised system validations (CSV) have become an area of increased scrutiny for regulatory agencies over the last several years. Understanding how the agencies view data integrity is critical for laboratories to maintain complete compliance.
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
High-content assays using 3D objects, such as cysts or organoids, can be challenging from the perspectives of both image acquisition and image analysis.
How to perform successful long term live cell imaging in a high-content analysis system.